ClinicalTrials.gg
WithdrawnNCT06552000Updated Oct 23, 2026

Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer

An interventional study of NovoTTF-200T System in NSCLC and Non Small Cell Lung Cancer, sponsored by University of Texas Southwestern Medical Center. Withdrawn at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by University of Texas Southwestern Medical Center · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
Sponsor deprioritized the study and made the choice to close the study.
Updated Oct 23, 2026Now WithdrawnStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Carcinoma, Non-Small-Cell Lung by University of Texas Southwestern Medical Center — 2 open to participants now, 4 under way, 1 of them phase 3. Carcinoma, Non-Small-Cell Lung · University of Texas Southwestern Medical Center.

Enrollment
20th of 22
0 · median 24
Started
2026
the only one that year
No phase
3 of 22
none open now
Registered
21st of 22
by date

Among the 22 studies in Carcinoma, Non-Small-Cell Lung by University of Texas Southwestern Medical Center, this one is the 20th largest by enrollment, is the only one that started in 2026, is one of 3 with no phase, and was the 21st registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 22 studies in Carcinoma, Non-Small-Cell Lung by University of Texas Southwestern Medical Center are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Carcinoma, Non-Small-Cell Lung by University of Texas Southwestern Medical Center, or all of them as a file.
02

Study summary

The purpose of this study is to study the clinical and biologic effects of Tumor Treatment Fields (TTFields) in patients undergoing resection of stage I-IIIA Non-Small Cell Lung Cancer (NSCLC). TTField is a non-invasive treatment that uses low-intensity electrical fields to treat cancer. Resection is the medical term for surgically removing part or all of a tissue, structure, or organ.

Read the detailed description

To study the clinical and biologic effects of Tumor Treatment Fields (TTFields) in patients undergoing resection of stage I-IIIA NSCLC.

Participants in this study will have a blood sample collected as well as vital signs along with a tumor tissue sample and tumor scan. Once it has been determined the participant can enroll into this study, he/she will come to the clinic for 5 scheduled visits over a period of 2 months .

03

Conditions studied

  • NSCLC
  • Non Small Cell Lung Cancer
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of stage I-IIIA NSCLC planned for surgical resection.
  2. (ECOG) 0-2 performance status.
  3. Willingness and ability to undergo planned correlative studies, including imaging tests.
  4. Fresh diagnostic material obtained from standard of care procedure to perform baseline correlatives (10-15 slides)-if not available, enrollment will be considered on a case-by-case basis after discussion with and approval by the Lead Site PI or Lead Site Co-Principal Investigator.
  5. Ability to understand and the willingness to sign a written .
  6. All men, as well as women of must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 30 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

    • 6a. A female of child-bearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
      • Has not undergone a hysterectomy or bilateral oophorectomy; or
      • Has not been naturally for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
  7. Age ≥22 years at time of screening.

Exclusion criteria

Exclusion Criteria:

  1. Receipt of prior therapy for the current NSCLC.
  2. Planned therapy for the current NSCLC.
  3. History of major allergic reactions attributed to adhesive or compounds in TTFields micro-array.
  4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements.
  5. Pregnant or nursing patients due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.
  6. Use of electronic devices or prosthetics - i.e., pacemakers, defibrillators, spinal infusion pumps. Specific scenarios can be discussed with the Lead Site PI or Lead Site Co-Principal Investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Tumor Treatment Fields

    Duration: 2-4 week; target 18 hours/day (on average). Continuous between time of enrollment and date of surgery. Cycle Length: 2-4 weeks

    Device: NovoTTF-200T System

Interventions

  • DeviceNovoTTF-200T System

    Exposure/Frequency: 150 kHz Route: Transdermal through patented microarray system to the hemithorax affected with cancer, 2-4 week duration, target 18 hours/day (on average)

06

What researchers measure

Primary outcomes

  1. Effect of TTF (Tumor-Treating Fields) on Fanconi anemia-related genes.

    Determine the effect of TTFields on expression of Fanconi anemia pathway-associated genes in NSCLC.

    Time frame: approximately 14-28 days

Secondary outcomes

  1. Safety of administering TTFields

    Assess the safety of administering TTFields prior to standard of care lung cancer resection. Analyses will be performed for all subjects having initiated TTFields therapy. The study will use the CTCAE version 5.0 for reporting of adverse events.

    Time frame: approximately 14-28 days

07

Study locations

1 site
  • The University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Oct 2026; primary completion for Dec 2029, 38 months later.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Oct 2026, on Oct 23, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2024
First posted
Aug 13, 2024
StartEst.
Oct 1, 2026was Jul 2026
Primary completionEst.
Dec 1, 2029
CompletionEst.
Dec 1, 2030
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn Sponsor deprioritized the study and made the choice to close the study.
changed Oct 23, 2026
Start date
Jul 1, 2026→Oct 1, 2026
Oct 23, 2026
Enrollment
18 (estimated)→0 (actual)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Not yet recruiting→Withdrawn
    Why stopped Sponsor deprioritized the study and made the choice to close the study.
    Start date Jul 1, 2026→Oct 1, 2026
    Enrollment 18 (estimated)→0 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06552000
Collaborators
NovoCure Ltd.
Responsible party
John Waters (Assistant Professor, Cardiovascular & Thoracic Surgery, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Aug 13, 2024
Start date
Oct 1, 2026 (estimated)
Primary completion
Dec 1, 2029 (estimated)
Completion
Dec 1, 2030 (estimated)
Last update
Oct 23, 2026

Study contacts

John Waters, MD
principal investigator · University of Texas Southwestern Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion